Advanced search
1 file | 383.17 KB

99mTc-(CO)3 His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab

(2011) JOURNAL OF NUCLEAR MEDICINE. 52(11). p.1786-1794
Author
Organization
Abstract
Colorectal tumors are dependent on angiogenesis for growth, and vascular endothelial growth factor (VEGF) is a key mediator of tumor angiogenesis. Antiangiogenic drugs can induce a transient normalization of the tumor vasculature with improved delivery of coadministered chemotherapy. The efficacy of antihuman VEGF antibody (bevacizumab) with or without irinotecan was evaluated in a colorectal cancer xenograft using Tc-99m-(CO)(3) His-annexin A5. Methods: Colo205-bearing mice were treated with a single dose of bevacizumab (5 mg/kg) during 2, 4, or 6 d. Microvessel density, pericyte coverage (alpha-smooth-muscle actin immunostaining), collagen-covered tumor vessels (Masson trichrome staining), and tumor hypoxic fraction (pimonidazole staining) were determined at the 3 different time points after treatment with bevacizumab. To investigate the possible synergistic effects of combination therapy with bevacizumab and irinotecan, Colo205-bearing mice were treated with a single dose of bevacizumab 2, 4, or 6 d before administration of a single dose of irinotecan (100 mg/kg) or 0.9% NaCl. The apoptosis-detecting radiotracer Tc-99m-(CO)(3) His-annexin A5 was injected (18.5 MBq) in mice 12, 24, and 48 h after the start of the irinotecan or NaCl treatment, and micro-SPECT was subsequently performed 3.5 h after injection of the radiotracer. Results were correlated to histologic analysis for apoptosis (caspase-3 activation). Results: Four days after bevacizumab administration, microvessel density decreased significantly, and alpha-smooth-muscle actin and collagen-covered vessels, compared with control tumors, were increased, suggesting normalization of the tumor vasculature. Hypoxic fraction was slightly reduced 4 d after treatment with bevacizumab. SPECT analyses demonstrated a significant increase in tumoral Tc-99m-(CO)(3) His-annexin A5 uptake 4 d after bevacizumab treatment and 24 h after irinotecan administration (232.78 +/- 24.82 percentage injected dose/tumor weight [g]/body weight [kg], P < 0.05), compared with each monotherapy, indicating a synergistic effect of both therapies. Conclusion: Tc-99m-(CO)(3) His-annexin A5 micro-SPECT demonstrates increased antitumor activity of irinotecan during the transient vascular normalization period caused by bevacizumab. Our data outline the importance of timing of combined anti-VEGF treatment with chemotherapy.
Keywords
CANCER, TUMORS, RADIATION, ANTIBODY, colorectal cancer, APOPTOSIS, THERAPY, chemotherapy delivery, Tc-99m-(CO)(3) His-annexin A5, vascular normalization, anti-VEGF

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 383.17 KB

Citation

Please use this url to cite or link to this publication:

Chicago
VANGESTEL, CHRISTEL, Christophe Van De Wiele, Nancy Van Damme, Steven Staelens, Patrick Pauwels, Chris PM Reutelingsperger, and Marc Peeters. 2011. “99mTc-(CO)3 His-annexin A5 micro-SPECT Demonstrates Increased Cell Death by Irinotecan During the Vascular Normalization Window Caused by Bevacizumab.” Journal of Nuclear Medicine 52 (11): 1786–1794.
APA
VANGESTEL, C., Van De Wiele, C., Van Damme, N., Staelens, S., Pauwels, P., Reutelingsperger, C. P., & Peeters, M. (2011). 99mTc-(CO)3 His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab. JOURNAL OF NUCLEAR MEDICINE, 52(11), 1786–1794.
Vancouver
1.
VANGESTEL C, Van De Wiele C, Van Damme N, Staelens S, Pauwels P, Reutelingsperger CP, et al. 99mTc-(CO)3 His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab. JOURNAL OF NUCLEAR MEDICINE. 2011;52(11):1786–94.
MLA
VANGESTEL, CHRISTEL, Christophe Van De Wiele, Nancy Van Damme, et al. “99mTc-(CO)3 His-annexin A5 micro-SPECT Demonstrates Increased Cell Death by Irinotecan During the Vascular Normalization Window Caused by Bevacizumab.” JOURNAL OF NUCLEAR MEDICINE 52.11 (2011): 1786–1794. Print.
@article{2141566,
  abstract     = {Colorectal tumors are dependent on angiogenesis for growth, and vascular endothelial growth factor (VEGF) is a key mediator of tumor angiogenesis. Antiangiogenic drugs can induce a transient normalization of the tumor vasculature with improved delivery of coadministered chemotherapy. The efficacy of antihuman VEGF antibody (bevacizumab) with or without irinotecan was evaluated in a colorectal cancer xenograft using Tc-99m-(CO)(3) His-annexin A5. Methods: Colo205-bearing mice were treated with a single dose of bevacizumab (5 mg/kg) during 2, 4, or 6 d. Microvessel density, pericyte coverage (alpha-smooth-muscle actin immunostaining), collagen-covered tumor vessels (Masson trichrome staining), and tumor hypoxic fraction (pimonidazole staining) were determined at the 3 different time points after treatment with bevacizumab. To investigate the possible synergistic effects of combination therapy with bevacizumab and irinotecan, Colo205-bearing mice were treated with a single dose of bevacizumab 2, 4, or 6 d before administration of a single dose of irinotecan (100 mg/kg) or 0.9\% NaCl. The apoptosis-detecting radiotracer Tc-99m-(CO)(3) His-annexin A5 was injected (18.5 MBq) in mice 12, 24, and 48 h after the start of the irinotecan or NaCl treatment, and micro-SPECT was subsequently performed 3.5 h after injection of the radiotracer. Results were correlated to histologic analysis for apoptosis (caspase-3 activation). Results: Four days after bevacizumab administration, microvessel density decreased significantly, and alpha-smooth-muscle actin and collagen-covered vessels, compared with control tumors, were increased, suggesting normalization of the tumor vasculature. Hypoxic fraction was slightly reduced 4 d after treatment with bevacizumab. SPECT analyses demonstrated a significant increase in tumoral Tc-99m-(CO)(3) His-annexin A5 uptake 4 d after bevacizumab treatment and 24 h after irinotecan administration (232.78 +/- 24.82 percentage injected dose/tumor weight [g]/body weight [kg], P {\textlangle} 0.05), compared with each monotherapy, indicating a synergistic effect of both therapies. Conclusion: Tc-99m-(CO)(3) His-annexin A5 micro-SPECT demonstrates increased antitumor activity of irinotecan during the transient vascular normalization period caused by bevacizumab. Our data outline the importance of timing of combined anti-VEGF treatment with chemotherapy.},
  author       = {VANGESTEL, CHRISTEL and Van De Wiele, Christophe and Van Damme, Nancy and Staelens, Steven and Pauwels, Patrick and Reutelingsperger, Chris PM and Peeters, Marc},
  issn         = {0161-5505},
  journal      = {JOURNAL OF NUCLEAR MEDICINE},
  keyword      = {CANCER,TUMORS,RADIATION,ANTIBODY,colorectal cancer,APOPTOSIS,THERAPY,chemotherapy delivery,Tc-99m-(CO)(3) His-annexin A5,vascular normalization,anti-VEGF},
  language     = {eng},
  number       = {11},
  pages        = {1786--1794},
  title        = {99mTc-(CO)3 His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab},
  url          = {http://dx.doi.org/10.2967/jnumed.111.092650},
  volume       = {52},
  year         = {2011},
}

Altmetric
View in Altmetric
Web of Science
Times cited: